Literature DB >> 16284780

Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome.

Barry W Brown1, Tracy J Costello, Shih-Jen Hwang, Louise C Strong.   

Abstract

Genetic anticipation is the increased incidence, earlier onset, or increased severity of a disease in successive generations. Before the biological basis of anticipation had been demonstrated, the phenomenon was thought to be due to sampling bias, epigenetic effects, gene conversion, or recombinant events. Since then, the biologic basis for anticipation in a number of neurodegenerative disorders has been shown to be attributable to trinucleotide repeat instability, with expansion of repeats clearly correlated with an earlier age of onset. Recently, telomere shortening has been suggested as the mechanism for anticipation in the autosomal dominant form of dyskeratosis congenita, attributable to mutations in the TERC gene, leading to dysfunctional telomeres (Vulliamy et al. 2004). However, the pattern of anticipation has been observed in other disorders, including cancers, for which no genetic defect has been identified. In this study, we assess the apparent generation effect on cancer incidence in ten extended families with P53 germline mutation, identified through probands diagnosed with childhood sarcoma. The probands were from two sets of systematically ascertained sarcoma patients treated at the University of Texas M. D. Anderson Cancer Center between 1944 and 1982. From those overall studies, we have identified ten kindreds having germline P53 mutations in more than one generation. We compared the cancer incidence in members of successive generations of these families with P53 mutations (carriers) and with no P53 mutations (noncarriers). In carriers, cancer incidence increased in succeeding generations; there was no evidence for this effect in noncarriers; however, the noncarrier population was too small to rule it out. The apparent lack of increase in incidence in noncarriers argues against a cohort effect explaining the increase in carriers.

Entities:  

Mesh:

Year:  2005        PMID: 16284780     DOI: 10.1007/s00439-005-0016-x

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  19 in total

1.  Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC.

Authors:  Tom Vulliamy; Anna Marrone; Richard Szydlo; Amanda Walne; Philip J Mason; Inderjeet Dokal
Journal:  Nat Genet       Date:  2004-04-18       Impact factor: 38.330

2.  Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.

Authors:  E D Lustbader; W R Williams; M L Bondy; S Strom; L C Strong
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

3.  The problem of anticipation in pedigrees of dystrophia myotonica.

Authors:  L S PENROSE
Journal:  Ann Eugen       Date:  1948-04

4.  Anticipation in familial leukemia.

Authors:  M Horwitz; E L Goode; G P Jarvik
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 5.  Anticipation: an old idea in new genes.

Authors:  M G McInnis
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

6.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

7.  Anticipation in myotonic dystrophy: fact or fiction?

Authors:  C J Höweler; H F Busch; J P Geraedts; M F Niermeijer; A Staal
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

8.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.

Authors:  Shih-Jen Hwang; Guillermina Lozano; Christopher I Amos; Louise C Strong
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

9.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  8 in total

1.  Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Authors:  R El Tannouri; E Albuisson; P Jonveaux; E Luporsi
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.

Authors:  Rodrigo Santa Cruz Guindalini; Andrew Song; James D Fackenthal; Olufunmilayo I Olopade; Dezheng Huo
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

3.  Mammary tumor modifiers in BALB/cJ mice heterozygous for p53.

Authors:  Joanna G Koch; Xiangjun Gu; Younghun Han; Adel K El-Naggar; Melissa V Olson; Daniel Medina; D Joseph Jerry; Anneke C Blackburn; Gary Peltz; Christopher I Amos; Guillermina Lozano
Journal:  Mamm Genome       Date:  2007-06-08       Impact factor: 2.957

4.  Transcriptional functionality of germ line p53 mutants influences cancer phenotype.

Authors:  Paola Monti; Yari Ciribilli; Jennifer Jordan; Paola Menichini; David M Umbach; Michael A Resnick; Lucio Luzzatto; Alberto Inga; Gilberto Fronza
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

5.  Genetic anticipation is associated with telomere shortening in hereditary breast cancer.

Authors:  Beatriz Martinez-Delgado; Kira Yanowsky; Lucia Inglada-Perez; Samuel Domingo; Miguel Urioste; Ana Osorio; Javier Benitez
Journal:  PLoS Genet       Date:  2011-07-28       Impact factor: 5.917

6.  Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.

Authors:  Tadashi Kumamoto; Fumito Yamazaki; Yoshiko Nakano; Chieko Tamura; Shimon Tashiro; Hiroyoshi Hattori; Akira Nakagawara; Yukiko Tsunematsu
Journal:  Int J Clin Oncol       Date:  2021-10-11       Impact factor: 3.402

Review 7.  Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Authors:  Pan Pantziarka; Sarah Blagden
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

8.  Number of rare germline CNVs and TP53 mutation types.

Authors:  Amanda G Silva; Isabel Maria W Achatz; Ana Cv Krepischi; Peter L Pearson; Carla Rosenberg
Journal:  Orphanet J Rare Dis       Date:  2012-12-21       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.